A dual-targeting system based on transferrin receptor (TfR)-binding peptide T12 and anti-PD-L1 nanobody modified liposomes (T12/P-Lipo) has been demonstrated to efficiently co-deliver simvastatin and gefitinib on brain metastasis of non-small cell lung cancer in mice, repolarizing and sensitizing the tumor-associated macrophages towards chemotherapy [125] (Figure 5b). The gene discussed is TFRC; the disease is non-small cell lung carcinoma.